1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )TABLE 4:Comparison of Known-Group Validity (Discrimination of 42 Patients with AD from 29 Control Subjects) with Other Linear CT-Based Measures of MTL Lobe Atrophy in CT Group
Control Group AD Group Sensitivity (95% CI)* Mean Crude Measure ± SD (mm) Mean Crude Measure ± SD (mm) Mean W-score ± SD Radial width of the temporal horn Right 2.9 ± 1.4 7.8 ± 3.0 3.6 ± 2.2 86% (71%–94%) Left 2.4 ± 1.3 7.8 ± 3.2 4.1 ± 2.4 83% (68%–92%) Largest 3.2 ± 1.2 9.1 ± 3.0 4.7 ± 2.4 93% (80%–98%) Transverse width of the temporal horn Right 1.0 ± 1.1 3.7 ± 1.9 2.2 ± 1.7 62% (46%–76%) Left 1.2 ± 1.3 4.3 ± 2.4 2.3 ± 1.9 57% (41%–72%) Largest 1.5 ± 1.3 4.7 ± 2.3 2.4 ± 1.9 64% (48%–78%) Minimum thickness of the medial temporal lobe Right 17.4 ± 2.3 10.9 ± 3.4 −2.7 ± 1.4 74% (58%–86%) Left 17.0 ± 3.1 11.6 ± 3.6 −1.9 ± 1.2 57% (41%–72%) Smallest 16.4 ± 2.8 10.2 ± 3.3 −2.4 ± 1.2 74% (58%–86%)
Note.—P < .001 for difference between groups on t test for all measures. W scores are age-standardized values; that is, the number of SD away from the age-specific atrophy value of control subjects (W scores in control subjects, 0.0 ± 1.0). Greater absolute values indicate greater atrophy.
* Values computed by modeling W scores of patients with AD and control subjects with specificity set at 95%.